Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen CME Grants Equal 0.4% Of Sales – More Than Pfizer, Less Than Lilly

Executive Summary

Educational grants and donations made by the Amgen Medical Education department totaled more than $11 million in the first quarter of 2008, according to an inaugural Web posting May 22

You may also be interested in...



Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Industry-Funded CME To Go Way Of Dinosaurs? ACCME Comments Lumber In

The pharmaceutical industry continues to retrench how it provides continuing medical education in response to public and congressional pressure, but firms are also marshalling for a fight against an outright ban

Related Content

UsernamePublicRestriction

Register

PS049660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel